| 1 | Estimating global prevalence,incidence,and outcomes of nonalcoholic fatty liver disease from 2000 to 2021:systematic review and meta-analysis显示文摘Background:The increasing burden of non-alcoholic fatty liver disease(NAFLD)worldwide imposes an emerging public health issue.We perform the current study to estimate the global prevalence,incidence,disease progression,and clinical outcomes of NAFLD.Methods:A systematic search was conducted in Medline,Embase,Web of Science,Google Scholar,and Cochrane CENTRAL that screened articles in English language published from January 2000 to December 2021.NAFLD prevalence,incidence,rate of disease progression,and outcomes were calculated with the DerSimonian-Laird random effects model with arcsine transformation.Results:Our search identified 59,156 records,of which 578 studies fulfilled our inclusion criteria.The overall prevalence of NAFLD was 29.38%(95%confidence interval[CI]28.09-30.69)regardless of the diagnostic techniques.Looking at the group in which the diagnosis was made by ultrasound exclusively,the pooled prevalence was 30.49%(95%CI 29.55-31.43).NAFLD has become more prevalent during the year 2011-2021(31.63%,95%CI 30.23-33.04)compared with year 2000-2010(27.94%,95%CI 26.23-29.69).The pooled estimation of non-alcoholic steatohepatitis prevalence was 8.26%(95%CI 1.13-21.01),46.49%(95%CI 35.93-57.20),and 46.72%(95%CI 37.57-55.98)in general population,NAFLD patients,and severe/morbidly obese patients,respectively.Based on a total of 110,142 newly developed NAFLD patients,the pooled incident rate was estimated as 46.24 cases per 1000 person-years(95%CI 43.21-49.30).In patients with NAFLD,the incident rate of hepatocellular carcinoma was 1.46(95%CI 0.90-2.03)cases per 1000 person-years.The overall pooled estimate of NAFLD related mortality was 23.91(95%CI 13.55-37.18)death per 1000 person-years.Conclusions:The prevalence of NAFLD is increasing globally.It is contributing to poor clinical outcomes including hepatocellular carcinoma and death.Rising awareness and urgent actions are warranted to control the NAFLD pandemic across the globe.Registration:PROSPERO,No.CRD42020171104. | Jiaye Liu Ye Tian Xia Fu Chunyang Mu Menglin Yao Yinyun Ni Yong Liu Zhihui Li | 2022 | Chinese Medical Journal2022，，14： | 4 |
| 2 | Point-of-care testing for lysine concentration in swine serum via blue-emissive carbon dot-entrapped microfluidic chip显示文摘Lysine is one of the essential amino acids and plays a vital role in the growth,development and health of pigs.Blood lysine concentration is a direct indication of lysine status;however,current methods can not satisfy the demands for rapid and on-site lysine concentration measurement of swine serum.Here,we developed blue-emissive nitrogen-doped carbon dots as a fluorescence probe for the determination of lysine with high fluorescence quantum yield,stability,sensitivity and specificity.The carbon dots were entrapped within hydrogel microstructures to fabricate microfluidic chips for rapid assay for lysine quantification.We further developed an imaging attachment to integrate the microfluidic chip and a smartphone into a portable point-of-care testing platform.This platform requires only 3μL sample and has a linear detection range of 25 to 300μmol/L with a limit of detection less than 16μmol/L,which covers the normal range of lysine concentration in swine serum.We tested lysine concentration in swine serum using this platform with high accuracy,low sample consumption,and within 3 min.Together,these results may provide a rapid and portable platform for dynamic monitoring of swine lysine status and contribute to precise feed formula modulation with low-protein diet strategy. | Chizhu Ding Xiang Chen Xiaoyu Chen Yue Liu Menglin Xia Ziyi He Qinshu Kang Xianghua Yan | 2023 | Animal Nutrition2023，，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员